Prevalence and Treatment of Pemphigus in Iran

Dermatologic Clinics

Volumn 29, Issue 4, 2011, Pages 681-683

  Chams Davatchi, Cheyda ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmune bullous disease; Management; Pemphigus; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TRIAMCINOLONE ACETONIDE;

BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; DQA1 GENE; DQB1 GENE; DRB GENE; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA ACQUISITA; FREQUENCY ANALYSIS; HAPLOTYPE; HISTOCOMPATIBILITY GENE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IGA PEMPHIGUS; IMMUNOFLUORESCENCE TEST; IRAN; MUCOUS MEMBRANE PEMPHIGOID; PARANEOPLASTIC PEMPHIGUS; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; PHENOTYPIC VARIATION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRAN; MALE; PEMPHIGUS; PREVALENCE;

EID: 80052895954     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.06.011     Document Type: Review

References (18)

1. Daneshpazhooh M, Chams-Davatchi C, Payandemehr P. Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Presented at 18th EADV Congress, October 7-10, 2009, Berlin/Germany. p. 152.
2. Chams-Davatchi C, Daneshpazhooh M, Esmaili N. Analysis of 1782 pemphigus. Presented at 21st World Congress of Dematology, October 1-5, 2007, Buenos Aires (Argentina);75:1190.
3. Shams S., Amirzargar A.A., Yousefi M., et al. HLA class II (DRB, DQA1 and DQB1) allele and haplotype frequencies in the patients with pemphigus vulgaris. J Clin Immunol 2009, 29:175-179.
4. Mobini N., Yunis E.J., Alper C.A. Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pemphigus vulgaris; possible common central Asian ancestral origin. Hum Immunol 1997, 57:62-67.
5. Chams- Davatchi C., Valikhani M., Daneshpazhooh M., et al. Pemphigus: analysis of 1209 cases. Int J Dermatol 2005, 44:470-476.
6. Balighi K., Taheri A., Mansoori P., et al. Value of direct immunofluorescence in predicting remission in pemphigus vulgaris. Int J Dermatol 2006, 45:1308.
7. Abasq C., Mouquet H., Gilbert D. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009, 145:529-535.
8. Chams-Davatchi C., Esmaili N., Daneshpazhooh M., et al. Randomized controlled open-label trial of 4 treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007, 57:622-628.
9. Martin L.K., Werth V., Villanueva E. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009, 1. CD006263.
10. Firooz A., Ghandi N., Hallaji Z., et al. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch Dermatol 2008, 144:1143-1147.
11. Beissert S., Minouni D., Kanvar A.J., et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010, 130:2041-2048.
12. Chams-Davatchi C., Nonahal Azar R., Daneshpazooh M., et al. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Ann Dermatol Venereol 2002, 129:23-25.
13. Joly P., Mouquet H., Roujeau J.C., et al. A single cycle for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
14. Schmidt E., Goebeler M., Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691.
15. Hertl M., Zilikens D., Borradori L., et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008, 6:366-373.
16. Lolis M., Toosi S., Czernick A., et al. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol 2011, 64(3):484-489.
17. Green M.G., Bystryn J.C. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008, 144:1621-1624.
18. Amagai M., Ikeda S., Shimizu H., et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009, 60:595-603.